Compare Nutanix Inc (NTNX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs TransMedics Group Inc — how do they compare? Nutanix Inc trades at $74.59 (market cap $19.78B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Nutanix Inc is far larger — about 7.2× TransMedics Group Inc's market cap, and Nutanix Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nutanix Inc for 17 Days and TransMedics Group Inc for 24 Days on average.
| NTNX | TMDX | |
|---|---|---|
Market Cap | $19.78B | $2.74B |
Volume | 1,717,619 | 949,331 |
Sector | Technology | Health |
52-Week High | $73.42 | $150.42 |
52-Week Low | $34.41 | $61.99 |
Typical Hold Time | 17 Days | 24 Days |
Enterprise Value | $18.94B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $74.63, up 1.65% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported robust revenue growth to $2.54B in 2025 and a net income margin of 52.81% in 2026, supported by leadership recognition in Gartner Magic Quadrant reports (GlobeNewsWire, 2026-09-16).
Outlook remains positive with a consensus price target of $76.11, though high valuation ratios like EV/EBITDA of 46.22 and an overbought RSI near 89.09 pose risks. Growth drivers include external storage and AI initiatives, but investor caution is warranted due to competitive pressures and supply-chain constraints noted in recent news (MarketBeat, 2026-09-14).
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
